---
schema_version: "secwatch.filing_event.v1"
accession: "0001639691-22-000094"
form_type: "8-K"
ticker: "LIVN"
cik: "0001639691"
company_name: "LivaNova PLC"
filed_at: "2022-10-11T23:59:59+00:00"
generated_at: "2026-06-23T04:25:29.497577+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# LivaNova RECOVER depression trial enrollment continues from 375 to 400 unipolar patients

## Summary
- Independent Statistical Analysis Committee advised continuation of RECOVER trial enrollment from 375 to 400 unipolar patients, per protocol.
- Trial includes frequent interim analyses every 25 patients to assess predictive probability of success.
- Upon meeting success criteria, RCT enrollment stops and patients enter open-label longitudinal study.
- Final analysis after last RCT patient completes 12 months follow-up; data to support peer-reviewed article.
- Success could lead to CMS reconsideration of reimbursement for VNS Therapy for difficult-to-treat depression.

## SEC filing metadata
- accession: 0001639691-22-000094
- form_type: 8-K
- ticker: LIVN
- cik: 0001639691
- company_name: LivaNova PLC
- filed_at: 2022-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1639691/000163969122000094/0001639691-22-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1639691/000163969122000094/livn-20221007.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001639691-22-000094
- JSON: https://secwatch.observer/filing/0001639691-22-000094.json
- Plain text: https://secwatch.observer/filing/0001639691-22-000094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.